Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 612

1.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

2.

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.

Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.

Retina. 2013 Sep;33(8):1605-12. doi: 10.1097/IAE.0b013e31828e8551.

PMID:
23549101
3.

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.

Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.

PMID:
23706500
4.

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.

Cho H, Shah CP, Weber M, Heier JS.

Br J Ophthalmol. 2013 Aug;97(8):1032-5. doi: 10.1136/bjophthalmol-2013-303344. Epub 2013 Jun 13.

PMID:
23766432
5.

Initial utilization of aflibercept in exudative age-related macular degeneration.

Cho H, Weber ML, Shah CP, Heier JS.

Eur J Ophthalmol. 2014 Jul-Aug;24(4):576-81. doi: 10.5301/ejo.5000421. Epub 2014 Mar 17.

PMID:
24706352
6.

Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.

Despreaux R, Cohen SY, Semoun O, Zambrowski O, Jung C, Oubraham H, Souied EH.

Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):639-44. doi: 10.1007/s00417-015-3084-1. Epub 2015 Jun 20.

PMID:
26092633
7.

Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.

Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK.

Am J Ophthalmol. 2013 Jul;156(1):29-35.e2. doi: 10.1016/j.ajo.2013.03.030. Epub 2013 May 10.

PMID:
23668679
8.

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).

Wykoff CC, Brown DM, Maldonado ME, Croft DE.

Br J Ophthalmol. 2014 Jul;98(7):951-5. doi: 10.1136/bjophthalmol-2013-304736. Epub 2014 Feb 11.

9.

One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration.

Arcinue CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR.

Am J Ophthalmol. 2015 Mar;159(3):426-36.e2. doi: 10.1016/j.ajo.2014.11.022. Epub 2014 Nov 18.

10.

Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration.

Heussen FM, Shao Q, Ouyang Y, Joussen AM, Müller B.

Graefes Arch Clin Exp Ophthalmol. 2014 Jun;252(6):909-15. doi: 10.1007/s00417-013-2553-7. Epub 2013 Dec 24.

PMID:
24362854
11.

INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.

Sarao V, Parravano M, Veritti D, Arias L, Varano M, Lanzetta P.

Retina. 2016 Apr;36(4):770-7. doi: 10.1097/IAE.0000000000000751.

PMID:
26398691
12.

Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results.

Grewal DS, Gill MK, Sarezky D, Lyon AT, Mirza RG.

Eye (Lond). 2014 Jul;28(7):895-9. doi: 10.1038/eye.2014.101. Epub 2014 May 16.

13.

PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.

de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I.

Retina. 2016 May;36(5):881-8. doi: 10.1097/IAE.0000000000000813.

PMID:
27115852
14.

Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.

Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D.

Ophthalmology. 2016 Dec;123(12):2545-2553. doi: 10.1016/j.ophtha.2016.08.016. Epub 2016 Oct 1.

PMID:
27707549
15.

Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD.

Waizel M, Rickmann A, Blanke BR, Wolf K, Kazerounian S, Szurman P.

Eur J Ophthalmol. 2016 Aug 4;26(5):469-72. doi: 10.5301/ejo.5000781. Epub 2016 Apr 12.

PMID:
27079204
16.

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Muftuoglu IK, Arcinue CA, Tsai FF, Alam M, Gaber R, Camacho N, You Q, Freeman WR.

Am J Ophthalmol. 2016 Jul;167:1-9. doi: 10.1016/j.ajo.2016.03.038. Epub 2016 Apr 2.

PMID:
27049000
17.

Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.

Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS, Falcão-Reis F, Carneiro ÂM.

Ophthalmologica. 2015;233(3-4):155-61. doi: 10.1159/000381221. Epub 2015 Apr 17.

PMID:
25896317
18.

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.

Inoue M, Yamane S, Sato S, Sakamaki K, Arakawa A, Kadonosono K.

Am J Ophthalmol. 2016 Sep;169:95-103. doi: 10.1016/j.ajo.2016.06.021. Epub 2016 Jun 16.

PMID:
27320059
19.

Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.

Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.

Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.

PMID:
26038338
20.

Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results.

Aghdam KA, Pielen A, Framme C, Junker B.

Eur J Ophthalmol. 2016 Aug 4;26(5):473-8. doi: 10.5301/ejo.5000757. Epub 2016 Feb 5.

PMID:
26868007

Supplemental Content

Support Center